Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00610857 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by Ahmad Tarhini.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00610857 is a Phase 2 study that has completed, run by Ahmad Tarhini. The registered enrollment target is 37 participants.
The verdict
NCT00610857, a Phase 2 study, has completed, sponsored by Ahmad Tarhini.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of the combination of HDI and anti-CTLA-4 monoclonal antibody for patients with recurrent inoperable stage III or stage IV melanoma.
Interventions
- DRUG Anti-CTLA4 monoclonal antibody and HDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2006-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00610857
The ClinicalTrials.gov registry entry for NCT00610857 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ahmad Tarhini, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-CTLA4 monoclonal antibody and HDI is the first listed.
NCT00610857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00610857 about?
NCT00610857 is a clinical study titled "Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma". To determine the safety and efficacy of the combination of HDI and anti-CTLA-4 monoclonal antibody for patients with recurrent inoperable stage III or stage IV melanoma.
What is the current status of trial NCT00610857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2006-11. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00610857?
The interventions under investigation include: Anti-CTLA4 monoclonal antibody and HDI (DRUG).
Who is sponsoring clinical trial NCT00610857?
This trial is sponsored by Ahmad Tarhini, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.